Controversies in the Management of Low-Risk Differentiated Thyroid Cancer
- PMID: 28633444
- PMCID: PMC5546880
- DOI: 10.1210/er.2017-00067
Controversies in the Management of Low-Risk Differentiated Thyroid Cancer
Abstract
Controversy exists over optimal management of low-risk differentiated thyroid cancer. This controversy occurs in all aspects of management, including surgery, use of radioactive iodine for remnant ablation, thyroid hormone supplementation, and long-term surveillance. Limited and conflicting data, treatment paradigm shifts, and differences in physician perceptions contribute to the controversy. This lack of physician consensus results in wide variation in patient care, with some patients at risk for over- or undertreatment. To reduce patient harm and unnecessary worry, there is a need to design and implement studies to address current knowledge gaps.
Copyright © 2017 Endocrine Society.
References
-
- Surveillance, Epidemiology, and End Results Program. Available at: www.seer.cancer.gov. Accessed 1 November 2016.
-
- Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A. AJCC Cancer Staging Manual. 7th ed New York, NY: Springer; 2010.
-
- Edge S, Greene FL, Byrd D, Brookland RK, Washington MK. AJCC Cancer Staging Manual. 8th ed New York, NY: Springer International Publishing; 2017.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
